{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:27:18Z","timestamp":1762918038973,"version":"3.37.3"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The natural history of cytomegalovirus (CMV) infection is complex. Individuals may experience primary infection, reactivation of latent infection, or reinfection with a new strain despite natural immunity. The ability of this virus to continue to replicate despite substantial immune responses is attributable to the many immune evasion genes encoded within its genome. Given this complex natural history and immunology, the design of clinical trials of CMV vaccines may require components not usually found in trials of vaccines designed to protect against viruses that cause only acute infections.<\/jats:p><jats:p>In this article, we focus on specific aspects of clinical trial design that could be adopted to address the complexities of CMV infections. We consider women of childbearing age, toddlers, recipients of solid organ transplantation, and stem cell transplant patients, emphasizing the parallels between women and solid organ transplantation that could allow vaccines to be developed in parallel in both these patient groups. We emphasize the potential for studies of passive immunity to inform the selection of immunogens as candidates for active immunization and vice versa. We also illustrate how application of whole-genomic sequencing could document whether vaccines protect against reactivation or reinfection of CMV or both.<\/jats:p>","DOI":"10.1093\/infdis\/jiz537","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T19:37:24Z","timestamp":1571341044000},"page":"S128-S134","source":"Crossref","is-referenced-by-count":5,"title":["Choice of Study Populations for Vaccines"],"prefix":"10.1093","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9317-5915","authenticated-orcid":false,"given":"Paul","family":"Griffiths","sequence":"first","affiliation":[{"name":"Institute for Immunity and Transplantation, UCL, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenna","family":"Hughes","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Duke University, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"key":"2020030507500935000_CIT0001","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1086\/514145","article-title":"Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation","volume":"176","author":"Cope","year":"1997","journal-title":"J Infect Dis"},{"key":"2020030507500935000_CIT0002","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1084\/jem.190.2.177","article-title":"The dynamics of human cytomegalovirus replication in vivo","volume":"190","author":"Emery","year":"1999","journal-title":"J Exp Med"},{"key":"2020030507500935000_CIT0003","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1600-6143.2004.00382.x","article-title":"Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients","volume":"4","author":"Paya","year":"2004","journal-title":"Am J Transplant"},{"key":"2020030507500935000_CIT0004","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am J Transplant"},{"key":"2020030507500935000_CIT0005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/rmv.513","article-title":"Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy","volume":"16","author":"Singh","year":"2006","journal-title":"Rev Med Virol"},{"key":"2020030507500935000_CIT0006","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0140-6736(00)02607-6","article-title":"Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants","volume":"356","author":"Limaye","year":"2000","journal-title":"Lancet"},{"key":"2020030507500935000_CIT0007","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/j.1600-6143.2012.04087.x","article-title":"Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy","volume":"12","author":"Atabani","year":"2012","journal-title":"Am J Transplant"},{"key":"2020030507500935000_CIT0008","doi-asserted-by":"crossref","first-page":"e0163722","DOI":"10.1371\/journal.pone.0163722","article-title":"Randomized controlled trials to define viral load thresholds for cytomegalovirus pre-emptive therapy","volume":"11","author":"Griffiths","year":"2016","journal-title":"PLoS One"},{"key":"2020030507500935000_CIT0009","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"2020030507500935000_CIT0010","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/cid\/cix793","article-title":"Use of viral load as a surrogate marker in clinical studies of cytomegalovirus in solid organ transplantation: a systematic review and meta-analysis","volume":"66","author":"Natori","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020030507500935000_CIT0011","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"2020030507500935000_CIT0012","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(84)90930-9","article-title":"Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants","volume":"1","author":"Plotkin","year":"1984","journal-title":"Lancet"},{"key":"2020030507500935000_CIT0013","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/S0140-6736(00)02350-3","article-title":"Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation","volume":"355","author":"Emery","year":"2000","journal-title":"Lancet"},{"key":"2020030507500935000_CIT0014","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.1958","article-title":"Criteria to define interruption of transmission of human cytomegalovirus from organ donor to recipient","volume":"28","author":"Baraniak","year":"2018","journal-title":"Rev Med Virol"},{"key":"2020030507500935000_CIT0015","doi-asserted-by":"crossref","first-page":"ofz003","DOI":"10.1093\/ofid\/ofz003","article-title":"Correlation of cytomegalovirus (CMV) disease severity and mortality with CMV viral burden in CMV-seropositive donor and CMV-seronegative solid organ transplant recipients","volume":"6","author":"McBride","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2020030507500935000_CIT0016","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1111\/ajt.14925","article-title":"A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor","volume":"18","author":"Vincenti","year":"2018","journal-title":"Am J Transplant"},{"key":"2020030507500935000_CIT0017","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/tid.12205","article-title":"Transient residence of a seropositive organ is sufficient to transfer human cytomegalovirus to a seronegative recipient","volume":"16","author":"Lumgair","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"2020030507500935000_CIT0018","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01794-16","article-title":"Phase 2 randomized, double-blind, placebo-controlled trial of RG7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in high-risk kidney transplant recipients","volume":"61","author":"Ishida","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020030507500935000_CIT0019","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/cid\/cit048","article-title":"Complex correlates of protection after vaccination","volume":"56","author":"Plotkin","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020030507500935000_CIT0020","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/rmv.535","article-title":"Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection","volume":"17","author":"Kenneson","year":"2007","journal-title":"Rev Med Virol"},{"key":"2020030507500935000_CIT0021","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.1921","article-title":"Maternal immune correlates of protection from human cytomegalovirus transmission to the fetus after primary infection in pregnancy","volume":"27","author":"Lilleri","year":"2017","journal-title":"Rev Med Virol"},{"key":"2020030507500935000_CIT0022","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01695-18","article-title":"Intrahost dynamics of human cytomegalovirus variants acquired by seronegative glycoprotein B vaccinees","volume":"93","author":"Nelson","year":"2019","journal-title":"J Virol"},{"key":"2020030507500935000_CIT0023","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N Engl J Med"},{"key":"2020030507500935000_CIT0024","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0264-410X(00)00377-7","article-title":"Encouraging prospects for immunisation against primary cytomegalovirus infection","volume":"19","author":"Griffiths","year":"2001","journal-title":"Vaccine"},{"key":"2020030507500935000_CIT0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-2334-7-71","article-title":"Incidence of cytomegalovirus infection among the general population and pregnant women in the United States","volume":"7","author":"Colugnati","year":"2007","journal-title":"BMC Infect Dis"},{"key":"2020030507500935000_CIT0026","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"key":"2020030507500935000_CIT0027","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1073\/pnas.1800177115","article-title":"HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions","volume":"115","author":"Nelson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020030507500935000_CIT0028","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1073\/pnas.1800224115","article-title":"Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies","volume":"115","author":"Baraniak","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020030507500935000_CIT0029","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ypmed.2012.03.009","article-title":"Awareness of and behaviors related to child-to-mother transmission of cytomegalovirus","volume":"54","author":"Cannon","year":"2012","journal-title":"Prev Med"},{"key":"2020030507500935000_CIT0030","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.ebiom.2015.08.003","article-title":"Prevention of primary cytomegalovirus infection in pregnancy","volume":"2","author":"Revello","year":"2015","journal-title":"EBioMedicine"},{"key":"2020030507500935000_CIT0031","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJMoa1310214","article-title":"A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus","volume":"370","author":"Revello","year":"2014","journal-title":"N Engl J Med"},{"key":"2020030507500935000_CIT0032","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000487302","article-title":"Histological analysis of term placentas from hyperimmune globulin-treated and untreated mothers with primary cytomegalovirus infection","volume":"45","author":"Gabrielli","year":"2019","journal-title":"Fetal Diagn Ther"},{"key":"2020030507500935000_CIT0033","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/rmv.1744","article-title":"The apparent paradox of maternal seropositivity as a risk factor for congenital cytomegalovirus infection: a population-based prediction model","volume":"23","author":"de Vries","year":"2013","journal-title":"Rev Med Virol"},{"key":"2020030507500935000_CIT0034","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/tid.12542","article-title":"Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants","volume":"18","author":"Panagou","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"2020030507500935000_CIT0035","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(86)92315-9","article-title":"Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow","volume":"1","author":"Wimperis","year":"1986","journal-title":"Lancet"},{"key":"2020030507500935000_CIT0036","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1473-3099(11)70344-9","article-title":"A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Kharfan-Dabaja","year":"2012","journal-title":"Lancet Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/Supplement_1\/S128\/32791380\/jiz537.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/Supplement_1\/S128\/32791380\/jiz537.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T01:14:46Z","timestamp":1664673286000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/221\/Supplement_1\/S128\/5781911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":36,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2020,3,5]]},"published-print":{"date-parts":[[2020,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz537","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"type":"print","value":"0022-1899"},{"type":"electronic","value":"1537-6613"}],"subject":[],"published-other":{"date-parts":[[2020,3,15]]},"published":{"date-parts":[[2020,3,5]]}}}